Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Schistosoma mansoni soluble egg antigen (SEA) is a complex mixture of proteins, glycoproteins, polysaccharides, and glycolipids extracted from homogenized eggs of the parasitic helminth Schistosoma mansoni[1][7]. SEA contains hundreds of components—many highly glycosylated—that are secreted by the eggs and play a central role in modulating host immune responses during infection[1][3][5]. Key constituents include immunomodulatory proteins such as omega-1 (a T2 ribonuclease), IPSE/alpha-1 (an interleukin-4-inducing principle), Sm-p40 (major egg antigen), and various micro-exon gene proteins (MEGs)[8]. Mechanistically, SEA skews immune responses toward Th2 dominance while suppressing Th1/Th17 pro-inflammatory pathways; it also promotes regulatory B cell and T cell development via effects on dendritic cells and macrophages[5][8]. These properties make it both a driver of schistosome-induced pathology (e.g., granulomatous inflammation) and an experimental tool for studying immunoregulation. Clinically, SEA is widely used as an antigen in serological assays for diagnosing schistosomiasis due to its strong immunogenicity[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Schistosoma mansoni soluble egg antigen.